DLA PIPER LLP (US) for BIOGEN, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR New | U.S. Senator |
| KARINA LYNCH New | — |
| MARGARET MARTIN New | Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr |
| MICHAEL SORENSEN New | Scheduler and other positions, Sen. Richard Burr; Intern, Rep. John Boehner; Intern, Rep. Mike Kelly |
Health Issues HCR
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR New | U.S. Senator |
| KARINA LYNCH New | — |
| MARGARET MARTIN New | Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr |
| MICHAEL SORENSEN New | Scheduler and other positions, Sen. Richard Burr; Intern, Rep. John Boehner; Intern, Rep. Mike Kelly |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.